DPP-IV阻害剤(シタグリプチン、ビルダグリプチン、サクサグリプチン、アログリプチン、 リナグリプチン)の世界市場

◆英語タイトル:DPP IV Inhibitors (Sitagliptin, Vildagliptin, Saxagliptin, Alogliptin, Linagliptin) : Global Strategic Business Report
◆商品コード:GIA60066
◆発行会社(調査会社):Global Industry Analysts
◆発行日:2016年4月
◆ページ数:192
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Single User(DRM付き)USD4,500 ⇒換算¥499,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Industry Analysts社の日本における正規販売代理店です。Global Industry Analysts社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、DPP-IV阻害剤(シタグリプチン、ビルダグリプチン、サクサグリプチン、アログリプチン、 リナグリプチン)の世界市場について調査・分析し、DPP-IV阻害剤(シタグリプチン、ビルダグリプチン、サクサグリプチン、アログリプチン、 リナグリプチン)の世界市場規模、市場動向、市場予測、関連企業情報などをお届けいたします。
【レポートの概要】

This report analyzes the worldwide markets for DPP IV Inhibitors in US$ Million. The Global market is analyzed by the following Drugs: Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors. The US market is analysed in terms of sales and number of prescriptions, by the following Drug Segments: Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 23 companies including many key and niche players such as –
AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck & Co, Inc.
Mitsubishi Tanabe Pharma Corporation

【レポートの目次】

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
Outlook for DPP-IV Therapies Remains Robust
Major Events in the DPP-IV Inhibitor Space
Table 1: Major
Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date
TECOS Results Prove Superiority of Januvia among Gliptins
Huge Potential Exists for Januvia and Other
Inhibitors
Table 2: Global
Inhibitor Market by Top Five Drug Class (2015): Percentage Market Share Breakdown of Revenues (includes corresponding Graph/Chart)
The Diabetes Epidemic
Global Diabetes Expenditure: Opportunity Indicator for DPP-IV Inhibitor Market
Table 3: Global Health Expenditure on Diabetes by Region (2015): Spending (in US$ Billion) by People Diagnosed with Diabetes in the Age Group 20-79 Years to Treat Diabetes and Manage Associated Complications (includes corresponding Graph/Chart)
Overview of Drug Classes in Anti-Diabetic Drugs Category
Complicated T2DM Management Protocol and the Role of DPP-IV Inhibitors
Inhibitors – Complementing Existing Approaches
Rationale for Use of
Inhibitors
Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction
Hunt for Novel Therapeutic Areas Attracts Pharma to
Market
Inhibitors versus
Receptor Agonists
Distinction between
Receptor Agonists and
Inhibitors
Inhibitors versus Sulfonylureas
2. A REVIEW OF SELECT APPROVED DRUGS, AND PIPELINE ANALYSIS
The
Inhibitor Domain
Select Approved
Inhibitors Available in Developed Markets
Januvia – The Leading DPP-IV Inhibitor Drug Worldwide
Galvus Sales Garner Significant Growth
A Comparison of Januvia and Galvus
Pharmacological Comparison of Sitagliptin and Vildagliptin
Januvia® Franchise (Merck & Co.)
Table 4: Global Sales of Januvia (Sitagliptin) Franchise by Region (2016E, 2018E, 2020E & 2022E): Value Sales in US$ Million for US and RoW(includes corresponding Graph/Chart)
Implantable Drug Pump: Potential Threat to Januvia?
Galvus (Novartis)
Onglyza (AstraZeneca)
Table 5: Global Sales of Onglyza (Saxagliptin) Franchise by Region (2016, 2018, 2020 & 2022): Value Sales in US$ Million for US and Rest of World (includes corresponding Graph/Chart)
Tradjenta (Boehringer Ingelheim)
TENELIA (Mitsubishi Tanabe Pharma Corporation & Daiichi Sankyo Co., Ltd.)
Nesina (Takeda Pharmaceutical)
ZAFATEK (Takeda Pharmaceutical)
MARIZEV (Merck)
Pipeline Analysis
DPP-IV Inhibitor Pipeline
Dutogliptin Development Shelved
3. DIABETES INCIDENCE AND PREVALENCE
Table 6: Global Diabetes Mellitus Incidence among Ages 20-79 (2015 & 2040P): Prevalence (in Million) and Percentage Share by Geographic Region (includes corresponding Graph/Chart)
Table 7: Top Ten Countries Worldwide with the Highest Number of People (in the Age Group 20-79 Years) with DM (in Millions): 2015 (includes corresponding Graph/Chart)
Diabetes Mellitus Cases Worldwide – A Demographic Analysis by Geographic Region
North America
The United States
Canada
Mexico
Table 8: Prevalence of Diabetes Mellitus in North America (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group for the US, Canada and Mexico (includes corresponding Graph/Chart)
Europe
Table 9: Prevalence of Diabetes Mellitus in Europe (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 47 Countries in the Region
Asia-Pacific
Table 10: Prevalence of Diabetes Mellitus in South East Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka
Table 11: Prevalence of Diabetes Mellitus in Western Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region
South & Central America
Table 12: Prevalence of Diabetes Mellitus in South & Central America (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 20 Countries in the Region
Rest of World
Table 13: Prevalence of Diabetes Mellitus in Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region
Table 14: Prevalence of Diabetes Mellitus in The Middle East & North Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 19 Countries in the Region
4. DPP-IV INHIBITORS – AN OVERVIEW OF THE DRUG CLASS
Physiology of Glucose Homeostasis
Glucose Homeostasis in the Fasting Stage
Glucose Homeostasis in the Fed Stage
What is
?
Introduction to
Inhibitors
Mechanism of Action of
Inhibitors
Schematic Representation of DPP-IV Inhibitor’ Mechanism of Action
Inhibitors in Combination with Other Anti-diabetic Medications
Advantages of
Inhibitors
Diabetes – The Most Prevalent Form of Diabetes
Bio-chemistry of T2DM
5. PRODUCT APPROVALS/INTRODUCTIONS
Mankind Pharma Launches Affordable Teneligliptin Drug
Zydus Cadila to Launch Tenglyn
Dong-A ST’s Evogliptin Drug SUGANON Receives Approval
PMDA Approves Merck’s MARIZEV® (omarigliptin) for Type 2 Diabetes
Glenmark Launches Teneligliptin under Ziten and Zita Plus Brands
Takeda Launches ZAFATEK
FDA Approves Glyxambi (linagliptin) by Boehringer and Lilly
EC Approves Takeda’s Alogliptin Fixed-Dose Combination Therapies
Mitsubishi Receives Approval for Partial Change in Indication for TENELIA
CFDA Approves Takeda’s NESINA
USFDA Approves Takeda’s NESINA, KAZANO and OSENI
6. RECENT INDUSTRY ACTIVITY
FDA Issues Heart Failure Risk Warning to Saxagliptin and Alogliptin Medicines
First Real-world Evidence Hints at Greater Efficacy of SGLT2 Inhibitors
FDA Issues CRL to AstraZeneca Regarding Investigational Drug
Lupin and Boehringer Announce Co-Marketing Agreement
FDA Issues Safety Warning about
Inhibitors
Merck’s TECOS Trial Meets Primary Endpoint
AstraZeneca Enters into Distribution Agreement with Dr.Reddy’s
AstraZeneca Files Lawsuit against Mylan for Patent Violation on Onglyza
BMS Completes Sale of Diabetes Business to AstraZeneca
Merck to Discontinue JUVISYNC Distribution to Pharmacies
Takeda and Sanofi Sign Co-Agreement to Market Alogliptin in China
Otsuka Pharmaceutical Receives Marketing Approval for Onglyza

7. FOCUS ON SELECT GLOBAL PLAYERS
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Eli Lilly and Company (US)
Merck & Co, Inc. (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Novartis AG (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)
8. GLOBAL MARKET PERSPECTIVE
Table 15: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 16: World Historic Review for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 17: World 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
Table 18: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 19: World Historic Review for DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 20: World 14-Year Perspective for DPP-IV Inhibitors by Drug Class - Percentage Breakdown of Dollar Sales for Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
A. Market Analysis
DPP-4 Inhibitors Set to Gain High Share in US Oral Anti-Diabetic Market
List of FDA-Approved
Inhibitors in the US: 2016
Diabetes Pandemic in the US
Table 21: Prevalence of Diabetes Mellitus in the US (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group (includes corresponding Graph/Chart)
Categories in Diabetes Treatment Market
Table 22: The US Anti-Diabetic Market by Drug Class (2015): Percentage Share Breakdown of Revenues for Insulin, DPP-4 & SGLT-2 Inhibitors, Analogues, Glitazones, PPARs, and Biguanides (includes corresponding Graph/Chart)
Increased Diabetes Spending Favors the
Inhibitor Market
Januvia Leads the Way, Will Continue to Maintain Dominance Through 2022
Table 23: The US
Inhibitors Market by Leading Brands (2016): Percentage Market Share Breakdown of Revenues for Januvia, Janumet, Tradjenta, Onglyza, Janumet XR, Kombiglyze, and Others (includes corresponding Graph/Chart)
Minimal Differentiation Affects Sales of Onglyza
Table 24: The US Anti-Diabetes Drugs in terms of Total Prescriptions (2015): Percentage Share of Metformin, Sulfonylureas, and
Inhibitors (Januvia, Onglyza, Tradjenta & Other) to the Total Non-Insulin Prescriptions (includes corresponding Graph/Chart)
FDA’s Issue of Safety Warning on
Inhibitors – Potential Market Threat
Increasing Scrutiny of NDAs Delays Time-to- Market for New Drugs
Product Approvals
Strategic Corporate Developments
Select Key Players
B. Market Analytics
Table 25: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 26: The US Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 27: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Compound - Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 28: The US 7-Year Perspective for DPP-IV Inhibitors by Drug Compound - Percentage Breakdown of Dollar Sales for Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs for Years 2016 and 2022 (includes corresponding Graph/Chart)
Table 29: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitor Prescriptions by Drug Compound: Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs Analyzed with Number of Prescriptions in Thousands for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 30: The US 7-Year Perspective for DPP-IV Inhibitors Prescriptions by Drug Compound - Percentage Breakdown of Prescriptions for Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs for Years 2016 and 2022 (includes corresponding Graph/Chart)
2. CANADA
A. Market Analysis
Table 31: Prevalence of Diabetes Mellitus in Canada (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group for Canada (includes corresponding Graph/Chart)
B. Market Analytics
Table 32: Canadian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 33: Canadian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
3. JAPAN
A. Market Analysis
Japan – An Important Market for DPP-IV Inhibitors
Table 34: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
Competition in the Japanese DPP-IV Inhibitor Market Heats Up
List of
Inhibitors in the Japanese Market (2016)
Product Approvals/Launches
Select Key Players
B. Market Analytics
Table 35: Japanese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 36: Japanese Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4. EUROPE
A. Market Analysis
Current & Future Analysis
DPP-IV Inhibitors Available in the European Market
Prevalence of Diabetes in Europe: Aging Population Dominate
Table 37: Prevalence of Diabetes Mellitus in Europe (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 47 Countries in the Region
Treatment Strategies of
Diabetes in Europe
Product Approval
B. Market Analytics
Table 38: European Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 39: European Historic Review for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 40: European 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Russia, and Rest of Europe Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
4a. FRANCE
Market Analysis
Table 41: French Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 42: French Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4b. GERMANY
A. Market Analysis
Boehringer Ingelheim GmbH – A Key Player
B. Market Analytics
Table 43: German Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 44: German Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4c. ITALY
Market Analysis
Table 45: Italian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 46: Italian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A. Market Analysis
Strategic Corporate Development
Astrazeneca plc. – a key player
B. Market Analytics
Table 47: The UK Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 48: The UK Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4e. RUSSIA
Market Analysis
Table 49: Russian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 50: Russian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4f. REST OF EUROPE
A. Market Analysis
Novartis Ag – A Key Switzerland-Based Player
B. Market Analytics
Table 51: Rest of European Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 52: Rest of European Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
A. Market Analysis
Asia-Pacific: The Fastest Growing Market for DPP-IV Inhibitors
Aging Populace – Potential Opportunities
Table 53: Over 65 Years Individuals as % of the Total Population in Select Asian Countries (includes corresponding Graph/Chart)
China & India Offer High Potential
Rising Diabetes Incidence in Asia-Pacific Offers Significant Growth Opportunities
Table 54: Prevalence of Diabetes Mellitus in South East Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka
Table 55: Prevalence of Diabetes Mellitus in Western Asia-Pacific Regions (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region
Asia Suffers from Lack of Focus on Diabetes Care
Healthcare Societies and Associations Spread Awareness of Diabetes
B. Market Analytics
Table 56: Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - China, India, South Korea, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 57: Asia-Pacific Historic Review for DPP-IV Inhibitors by Geographic Region - China, India, South Korea, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 58: Asia-Pacific 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for China, India, South Korea, and Rest of Asia-Pacific Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
5a. CHINA
A. Market Analysis
Current & Future Analysis
China: A Market with Huge Untapped Potential for
Inhibitor Drugs
Robust Growth Ahead Despite Initial Lag
Product Approval
Strategic Corporate Development
B. Market Analytics
Table 59: Chinese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 60: Chinese Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
5b. INDIA
A. Market Analysis
Inhibitor to Garner Increasing Share in Indian Diabetes Drugs Market
First-to-Market Advantage and Unique Strategy Keep Januvia Ahead of Competition
Diabetic Epidemic in the Country Spurs Market Growth
Product Launches
Strategic Corporate Developments
B. Market Analytics
Table 61: Indian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 62: Indian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
5c. SOUTH KOREA
A. Market Analysis
Rising Competition in the Korean
Inhibitor Market
Table 63: Korean
Inhibitor Market (2009-2015): No. of
Inhibitors on the Market during 2009, 2010, 2011, 2012, 2013, 2014 & 2015 (includes corresponding Graph/Chart)
Product Approval
B. Market Analytics
Table 64: South Korean Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 65: South Korean Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
5d. REST OF ASIA-PACIFIC
A. Market Analysis
Current & Future Analysis
Australia
Rising Incidence of Diabetes
B. Market Analytics
Table 66: Rest of Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 67: Rest of Asia-Pacific Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
6. REST OF WORLD
A. Market Analysis
Current & Future Analysis
Latin America: National Diabetes Programs
A Peek at Brazilian Diabetes Market
Table 68: Prevalence of Diabetes Mellitus in South & Central America (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 20 Countries in the Region
United Arab Emirates: Rising Diabetic Cases to Propel Market Demand
Key Statistics: Diabetes Prevalence in Middle East and African Regions
Table 69: Prevalence of Diabetes Mellitus in Middle East & North Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 19 Countries in the Region
Table 70: Prevalence of Diabetes Mellitus in Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region
B. Market Analytics
Table 71: Rest of World Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 72: Rest of World Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 23
The United States (3)
Japan (7)
Europe (4)
- Germany (1)
- The United Kingdom (1)
- Spain (1)
- Rest of Europe (1)
Asia-Pacific (Excluding Japan) (9)

★調査レポート[DPP-IV阻害剤(シタグリプチン、ビルダグリプチン、サクサグリプチン、アログリプチン、 リナグリプチン)の世界市場]販売に関する免責事項
★調査レポート[DPP-IV阻害剤(シタグリプチン、ビルダグリプチン、サクサグリプチン、アログリプチン、 リナグリプチン)の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆